Product Description
Amodiaquine is an orally active 4-aminoquinoline derivative with antimalarial and anti-inflammatory properties. Similar in structure and activity to chloroquine, amodiaquine is effective against some chloroquine-resistant strains, particularly Plasmodium falciparum, the most deadly malaria parasite. Although the mechanism of plasmodicidal action has not been fully elucidated, like other quinoline derivatives, amodiaquine likely is able to inhibit heme polymerase activity in the body. This results in accumulation of free heme, which is toxic to the parasites. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amodiaquine)
Mechanisms of Action: ACHE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: China | Cyprus | Egypt | India | Korea | Malaysia | Pakistan | Peru | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Thailand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: HIV Infections|Hepatitis B|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ALAQ | P1 |
Recruiting |
Pregnancy Outcomes|Hepatitis B|HIV Infections |
2026-08-31 |